Payment overview · 2025
General Payments
$203.97
12 reported records · 8 companies
Healthcare provider profile · identity verified
John E Hatzantonis, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BRIDGETON, NJ · NPI 1467551374
Verified facts
What the public records show
CMS Open Payments records show John E Hatzantonis, MD received $203.97 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 30.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.96 | 30.9% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.63 | 16.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.19 | 13.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.99 | 8.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.33 | 8.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.90 | 7.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.28 | 7.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.69 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $203.97 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.96 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.96 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $32.63 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.19 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.19 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 118 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
46 | 44 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 816 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 609 | 113 |
| Eliquis | Apixaban | 606 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 442 | 102 |
| Omeprazole | Omeprazole | 383 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 379 | 74 |
| Losartan Potassium | Losartan Potassium | 349 | 80 |
| Furosemide | Furosemide | 334 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 324 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 57 |
| Gabapentin | Gabapentin | 258 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 251 | 59 |
| Donepezil Hcl | Donepezil Hcl | 245 | 35 |
| Lisinopril | Lisinopril | 239 | 61 |
| Memantine Hcl | Memantine Hcl | 220 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 204 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 195 | 55 |
| Metformin Hcl | Metformin Hcl | 192 | 53 |
| Simvastatin | Simvastatin | 185 | 40 |
| Finasteride | Finasteride | 184 | 27 |
| Sertraline Hcl | Sertraline Hcl | 180 | 27 |
| Carvedilol | Carvedilol | 177 | 34 |
| Famotidine | Famotidine | 174 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 166 | 38 |
| Potassium Chloride | Potassium Chloride | 164 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 32 |
| Mirtazapine | Mirtazapine | 148 | 26 |
| Myrbetriq | Mirabegron | 145 | 13 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 139 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 132 | 32 |
| Jardiance | Empagliflozin | 118 | 15 |
| Cefuroxime | Cefuroxime Axetil | 116 | 101 |
| Alprazolam | Alprazolam | 112 | 27 |
| Ipratropium Bromide | Ipratropium Bromide | 111 | 29 |
| Prednisone | Prednisone | 110 | 65 |
| Quetiapine Fumarate | Quetiapine Fumarate | 105 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 100 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 98 | 23 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 98 | 11 |
| Buspirone Hcl | Buspirone Hcl | 96 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 16 |
| Azithromycin | Azithromycin | 90 | 81 |
| Montelukast Sodium | Montelukast Sodium | 87 | 17 |
| Glimepiride | Glimepiride | 86 | 24 |
| Trazodone Hcl | Trazodone Hcl | 86 | 21 |
| Albuterol Sulfate | Albuterol Sulfate | 82 | 28 |
| Humalog Kwikpen U-100 | Insulin Lispro | 82 | 12 |
| Insulin Aspart Flexpen | Insulin Aspart | 79 | 13 |
| Ezetimibe | Ezetimibe | 78 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 26 |
| Allopurinol | Allopurinol | 71 | 16 |
| Xarelto | Rivaroxaban | 71 | suppressed |
| Januvia | Sitagliptin Phosphate | 70 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 68 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 67 | 16 |
| Atenolol | Atenolol | 65 | 15 |
| Levetiracetam | Levetiracetam | 64 | 11 |
| Methylprednisolone | Methylprednisolone | 64 | 59 |
| Repaglinide | Repaglinide | 64 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 46 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 60 | suppressed |
| Entresto | Sacubitril/Valsartan | 60 | suppressed |
| Latanoprost | Latanoprost | 59 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 59 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | suppressed |
| Cefdinir | Cefdinir | 56 | 43 |
| Tradjenta | Linagliptin | 54 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 35 |
| Amiodarone Hcl | Amiodarone Hcl | 53 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | suppressed |
| Pregabalin | Pregabalin | 49 | 16 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 46 | 44 |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 44 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 43 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 43 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Folic Acid | Folic Acid | 42 | suppressed |
| Meloxicam | Meloxicam | 42 | 19 |
| Mupirocin | Mupirocin | 42 | 28 |
| Celecoxib | Celecoxib | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Lactulose | Lactulose | 39 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 37 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | suppressed |
| Levemir Flexpen | Insulin Detemir | 37 | suppressed |
| Silodosin | Silodosin | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Ketoconazole | Ketoconazole | 35 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Cephalexin | Cephalexin | 33 | 18 |
| Irbesartan | Irbesartan | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | 14 |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Sotalol | Sotalol Hcl | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 26 |
| Baclofen | Baclofen | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 14 |
| Levofloxacin | Levofloxacin | 28 | 22 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Nystatin | Nystatin | 23 | 15 |
| Amoxicillin | Amoxicillin | 22 | 19 |
| Erythromycin | Erythromycin Base | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 12 |
| Risperidone | Risperidone | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | 14 |
| Arformoterol Tartrate | Arformoterol Tartrate | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | 13 |
| Lumigan | Bimatoprost | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Lamivudine-Zidovudine | Lamivudine/Zidovudine | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Acetylcysteine | Acetylcysteine | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Efavirenz | Efavirenz | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Pulmicort | Budesonide | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $203.97 · 12 records | Novo Nordisk Inc | JARDIANCE, Kerendia, LEQVIO, MOUNJARO, Ozempic, REXULTI, Rybelsus, SHINGRIX, ZEPBOUND, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error